Evidence map›Paper›PMID 40985724›Full record

ArticlemSphere2025

Testing the Luedemann hypothesis: the discovery of novel antimicrobials from slow-growing microbes from nutrient-limited environments.

Brendan Lin, Sunmin Woo, Alesa Philbrick, John Bacsa, Emily Laskey, Nancy Mehra, Vijay S Gondil, Jia A Mei, George Jones, Martin S Pavelka and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mSphere, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Brendan Lin *Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, USA.
Sunmin Woo *Center for the Study of Human Health, Emory University College of Arts and Sciences, Atlanta, Georgia, USA.ORCID 0000-0001-7561-2333
Alesa PhilbrickDepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, USA.
John BacsaDepartment of Chemistry, Emory University College of Arts and Sciences, Atlanta, Georgia, USA.
Emily LaskeyDepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, USA.
Nancy MehraDepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, USA.
Vijay S GondilDepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, USA.ORCID 0000-0001-5603-7345
Jia A MeiDepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, USA.
George JonesDepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, USA.
Martin S PavelkaDepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, USA.ORCID 0000-0003-3265-8555
Michelle DziejmanDepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, USA.ORCID 0000-0002-3960-0703
Daniel A ShutterDepartment of Chemistry and Biochemistry, Notre Dame University, South Bend, Indiana, USA.
Christian MelanderDepartment of Chemistry and Biochemistry, Notre Dame University, South Bend, Indiana, USA.ORCID 0000-0001-8271-4696
Alexander M PerrittPerritt Laboratories, Hightstown, New Jersey, USA.
Rick JakoberPerritt Laboratories, Hightstown, New Jersey, USA.
Yaoyao ShenDepartment of Chemistry, North Carolina State University, Raleigh, North Carolina, USA.ORCID 0000-0002-1785-9001
Wei-Chen ChangDepartment of Chemistry, North Carolina State University, Raleigh, North Carolina, USA.ORCID 0000-0002-2341-9846
Cassandra L QuaveCenter for the Study of Human Health, Emory University College of Arts and Sciences, Atlanta, Georgia, USA.ORCID 0000-0001-9615-7886
Paul M DunmanDepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, USA.ORCID 0000-0001-5138-521X
George LuedemannIndependent Researcher, Amado, Arizona, USA.

Funding

Development and validation of a high-throughput MicroED-driven platform technology for natural product discoveryR01AT011990 · NCCIH · EMORY UNIVERSITY · PI Hosea Martin Nelson, CASSANDRA LEAH QUAVE · 2022 to 2026
$3.2M
NCCIH NIH HHS R01 AT011990NIH HHS R01AT011990
6 · The paper itself

Abstract

George Luedemann is known throughout the antimicrobial community as one of the discoverers of the natural product antibiotic gentamicin. He subsequently hypothesized that slow-growing organisms inhabiting inhospitable, nutrient-limited environments may represent an enriched source of previously undescribed microbes that produce novel antimicrobials to create a competitive advantage over faster-growing rival organisms. Accordingly, 750 slow-growing microorganisms were isolated from desert rock surfaces and archived prior to Dr. Luedemann's passing in 2000. Here, we describe the characterization and antimicrobial screening of the first 147 members of the Luedemann collection. 16S rRNA and whole-genome sequencing revealed that the pilot isolate set is highly diverse and includes novel microbial species belonging to genera commonly associated with soil samples, including

Indexed as

Anti-Bacterial AgentsAnti-Infective AgentsBacteriaSoil MicrobiologyMicrobial Sensitivity TestsNutrientsPhylogenyPyocyanineRNA, Ribosomal, 16SWhole Genome SequencingAnti-Bacterial AgentsAnti-Infective AgentsNutrientsPyocyanineRNA, Ribosomal, 16SAcinetobacter baumanniiantimicrobialnatural product

Identifiers

PMID40985724
PMCPMC12570475

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.